Overview

A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

Status:
Not yet recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of daratumumab in adult ITP patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including rituximab and/or TPO-RA.

Phase:

Early Phase 1

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Treatments:

Daratumumab